End-Stage Renal Disease (ESRD) Clinical Trial
Hearing impairment either clinical or subclinical is a characteristic of some renal disease patients. The hearing impairment could be result from specific etiologies or chronic renal failure itself. The causes of hearing impairment in renal disease patients ranged from drugs intoxication in both auditory and renal function, like gentamycin or isoniazid, congenital disease like Alport syndrome or other collagen-defective renal disease, or just aging related. End-stage renal disease (ESRD) patients are special in many parts to general population who have hearing impairment. First, inflammation in ESRD patients is well-documented, second, they suffered from various underlying diseases which auditory function was potentially impaired, third, they need to undergo renal replacement therapy either hemodialysis (HD) or peritoneal dialysis (PD) to maintain their life. Dialysis itself was found to be a cause of hearing impairment, too. The biochemical change and constitutive inflammation status are thought to be implicated in the pathogenesis of hearing impairment in ESRD patients. Aluminum (Al) is a well-documented heavy metal, which predisposes to Alzheimer’s disease, dementia or some neurologic diseases. Al intoxication is very rare in general health population but elevated serum Al level is easily found in ESRD patients since they can not excrete Al by damaged kidneys and dialyzers. Inner ear per se is a neurologic tissue, so if serum Al level in ESRD patients has any association in their haring function needs to be studied.
n/a
Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Cross-Sectional
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02553889 -
A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis
|
Phase 2 | |
| Completed |
NCT01222234 -
Impact of Vitamin D Therapies on Chronic Kidney Disease
|
N/A | |
| Active, not recruiting |
NCT03989141 -
Creating a Buttonhole Tunnel Track by Repeated Needling of the AV Fistula on the Same Day in Patients on Hemodialysis.
|
N/A | |
| Completed |
NCT01526798 -
Improvement of EPO-resistance in Hemodialysis Patients With Chronic Inflammation by High Cut-off Hemodialysis
|
N/A | |
| Completed |
NCT05285787 -
A Clinical Trial of Epizon-701 (EPN-701) in Subjects With End-Stage Renal Disease (ESRD)
|
Phase 2 | |
| Completed |
NCT05769595 -
Single Dose Study of MK-2060 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Older Japanese Participants on Dialysis (MK-2060-012)
|
Phase 1 | |
| Completed |
NCT03119818 -
Intracellular Phosphate Concentration Evolution During Hemodialysis by MR Spectroscopy
|
N/A | |
| Completed |
NCT01228279 -
Sympathetic Activity in Patients With End-stage Renal Disease on Peritoneal Dialysis
|
Phase 4 | |
| Completed |
NCT02502903 -
Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders
|
Phase 1 | |
| Enrolling by invitation |
NCT06243900 -
NIRS for the Diagnosis of Residual Renal Function Injury in Hemodialysis Patients
|
||
| Completed |
NCT03358030 -
A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Stage Renal Disease (ESRD) on Hemodialysis
|
Phase 2 | |
| Recruiting |
NCT01415570 -
Malnutrition, Diet and Racial Disparities in Chronic Kidney Disease (CKD)
|
N/A | |
| Completed |
NCT00548249 -
Dose Ranging Study of Dialysate Containing Soluble Iron to Treat Subjects With End Stage Renal Disease (ESRD) Receiving Chronic Hemodialysis
|
Phase 2 |